Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17947420 | 1.00 | AR (0.74) | AR | |
| SCHEMBL29817494 | 1.00 | AR (0.74) | AR | |
| SCHEMBL22557766 | 1.00 | AR (0.74) | AR | |
| SCHEMBL24379224 | 0.88 | AR (0.73) | AR | |
| SCHEMBL28661718 | 0.87 | AR (0.58) | AR | |
| SCHEMBL28661716 | 0.87 | AR (0.58) | AR | |
| SCHEMBL29817560 | 0.87 | AR (0.63) | AR | |
| SCHEMBL27169517 | 0.86 | AR (0.84) | AR | |
| SCHEMBL17941144 | 0.86 | AR (0.84) | AR | |
| SCHEMBL23594154 | 0.86 | AR (0.57) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577231-B2 | Androgen receptor PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-01 | — | — | US | disclosed |
| WO-2025226797-A1 | KRED CATALYZED KETOREDUCTION OF A CYCLOBUTANONE CARBAMIC ESTER | GENENTECH, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-06-26 | — | — | US | disclosed |
| WO-2025061906-A1 | ANDROGEN RECEPTOR PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-03-27 | — | — | WO | disclosed |
| EP-4499628-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-02-05 | — | — | EP | disclosed |
| US-12006314-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2024-06-11 | — | — | US | disclosed |
| WO-2024054603-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-4334314-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2023180388-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-20230091225-A1 | Bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2023-03-23 | — | — | US | disclosed |
| US-20220380364-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-12-01 | — | — | US | disclosed |
| WO-2022235585-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-4077309-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230091225-A1 | Bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof | AR, ADRM1, PSMA1 | AR 1/4885 |
| US-20220380364-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | AR 9/4885 |
| US-12006314-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NR5A1, NCOA1, NR5A2 | AR 4/4885 |
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | AR, CRBN, PSMA3 | AR 1/4885 |
| US-12577231-B2 | Androgen receptor PROTACS | AR, CRBN, PSMA3 | AR 1/4885 |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | CRBN, AR, GNRHR | AR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.